Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02722278 · ClinicalTrials.gov registry record · Phase 3

A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

A Phase 3 study, sponsored by Clarus Therapeutics.

Completed
Registry status
Phase 3
Development phase
222
Enrollment target

NCT02722278: Completed Phase 3 study, sponsored by Clarus Therapeutics.

NCT02722278 is a Phase 3 study that has completed, run by Clarus Therapeutics. The registered enrollment target is 222 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02722278, a Phase 3 study, has completed, sponsored by Clarus Therapeutics.

COMPLETED
Registry status
Phase 3
Development phase
222 participants
Enrollment target

Study Summary

A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

Interventions

  • DRUG Oral Testosterone Undecanoate
  • DRUG Axiron Testosterone Topical Solution

Trial Details

FieldValue
Enrollment Target 222 participants
Start Date 2016-03
Est. Completion 2016-11
Phase Phase 3
Clarus Therapeutics

11 total trials

What the finished NCT02722278 record still lists

NCT02722278 is an interventional study that assigns participants to a tested intervention. The registered 222 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).

The record links to 0 conditions, and to 2 interventions - of which Oral Testosterone Undecanoate is the first listed.

NCT02722278 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02722278 about?

NCT02722278 is a clinical study titled "A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men". A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

What is the current status of trial NCT02722278?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 222 participants. The study started on 2016-03. Estimated completion is 2016-11.

What interventions are being tested in trial NCT02722278?

The interventions under investigation include: Oral Testosterone Undecanoate (DRUG), Axiron Testosterone Topical Solution (DRUG).

Who is sponsoring clinical trial NCT02722278?

This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02722278's enrollment target sits among peer trials

222 1317th of 2000 higher than 683 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04939610 · 222 participants · Phase 1

    A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

  • NCT05424783 · 222 participants

    MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)

  • NCT05568264 · 222 participants · NA

    Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

  • NCT05605574 · 222 participants · NA

    Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02722278, the US trial registry maintained by the National Library of Medicine. NCT02722278 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.